Brad Briggs is the Managing Editor of StreetAuthority. A veteran of the financial publishing industry, Brad manages the team of writers and editors responsible for our premium newsletters as well as the free content in our ezines and on our website. He is also the managing editor and a regular contributor for StreetAuthority's premium newsletter, StreetAuthority Insider.
Brad took an interest in the stock market at a young age, buying his first equities in high school. After graduating early from Baylor University, success in the market enabled him to pay off student loans and afford the downpayment on his first house. So instead of pursuing a career in journalism, he decided to follow his interest in the stock market, and he's been hooked ever since then.
Brad believes that successful investing doesn't have to be complicated, and that anyone can achieve financial independence no matter their background. As Managing Editor, Brad makes it his mission to demystify the world of investing, making it easy to understand for a wide audience. His writing has been featured in outlets like Yahoo Finance, Nasdaq.com, and MSN Money, among others.
When he's not following the market, Brad spends his time doing CrossFit, reading about history, and working cattle in East Texas.
Analyst Articles
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings...
Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings season, while the S&P is up +10% for the year. The market couldn’t have made it to this...
Read More
The largest savings and loan in the United States said second-quarter earnings were up 16% from last year. Net income rose to $127.9 million, or 26 cents a share, compared with $110.7 million, or 22 cents a… Read More
Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
Healthcare giant Johnson & Johnson (NYSE: JNJ) said this morning that second-quarter earnings amounted to $1.15 a share. The results, a -4.7% decline from a year ago, beat expectations, despite challenges facing the company’s pharmaceutical unit and a stronger dollar. The company said… Read More
A key measure of wholesale prices rose in June at nearly twice the increase economists had forecast. It was the sharpest rise for the index since November 2007. The Producer Price Index, which tracks how much it costs for manufacturers to make things,… Read More
The first half of 2009 has been nothing short of volatile for Wall Street. Between corporate bailouts, bankruptcies and unprecedented government spending, the news has been full of surprises. The assorted high-profile shenanigans of GM, AIG and others deserve their rightful place in the “Hall of Shame,” but there has… Read More
Nathan, some investors may feel we’ve found ourselves in uncharted territory during this market, but you seem to think value investors should be salivating right now. Why? Nathan Slaughter: There are always bargains to be had in the market. Unfortunately, during normal conditions value hunters looking for deeply underpriced… Read More
